Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.


Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

GlobeNewswire July 18, 2022

IIROC Trading Halt - AGN

Canada NewsWire July 15, 2022

Algernon Pharmaceuticals (CSE:AGN) updates its planned Phase 1 Repirinast Chronic Kidney Disease study

John Ballem  July 11, 2022

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

GlobeNewswire July 11, 2022

Algernon Pharmaceuticals (CSE:AGN) updates Phase 1 DMT human stroke study

John Ballem  July 7, 2022

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

GlobeNewswire July 7, 2022

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

GlobeNewswire July 5, 2022

Algernon Pharmaceuticals Inc. (CSE:AGN) closes public offering of units

Azuka Onwuka July 4, 2022

Algernon Pharmaceuticals Announces Closing of Public Offering of Units

GlobeNewswire July 4, 2022

Algernon Pharmaceuticals (CSE:AGN) announces pricing of public offering

John Ballem  June 27, 2022

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

GlobeNewswire June 27, 2022

Algernon Pharmaceuticals (CSE:AGN) receives patent for Ifenprodil

John Ballem  June 22, 2022

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire June 22, 2022

Algernon (CSE:AGN) receives requests for ongoing supply of Ifenprodil from study participants

Azuka Onwuka June 21, 2022

Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

GlobeNewswire June 21, 2022

Algernon Pharmaceuticals (CSE:AGN) announces public offering of units

John Ballem  June 16, 2022

Algernon Pharmaceuticals Announces Public Offering of Units

GlobeNewswire June 15, 2022

Algernon Pharmaceuticals (CSE:AGN) locks in Phase 2 results of IPF & chronic cough study

Jon Brown June 13, 2022

Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

GlobeNewswire June 13, 2022

Algernon Pharmaceuticals (CSE:AGN) treats last patient in phase 2 IPF and chronic cough study

Trevor Abes  May 5, 2022